Cargando…

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges

At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Pengxiao, Zhang, Ming, Kang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028134/
https://www.ncbi.nlm.nih.gov/pubmed/36959792
http://dx.doi.org/10.3389/fonc.2023.1071030
_version_ 1784909876686749696
author Su, Pengxiao
Zhang, Ming
Kang, Xin
author_facet Su, Pengxiao
Zhang, Ming
Kang, Xin
author_sort Su, Pengxiao
collection PubMed
description At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms.
format Online
Article
Text
id pubmed-10028134
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100281342023-03-22 Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges Su, Pengxiao Zhang, Ming Kang, Xin Front Oncol Oncology At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028134/ /pubmed/36959792 http://dx.doi.org/10.3389/fonc.2023.1071030 Text en Copyright © 2023 Su, Zhang and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Su, Pengxiao
Zhang, Ming
Kang, Xin
Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
title Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
title_full Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
title_fullStr Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
title_full_unstemmed Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
title_short Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
title_sort targeting c-met in the treatment of urologic neoplasms: current status and challenges
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028134/
https://www.ncbi.nlm.nih.gov/pubmed/36959792
http://dx.doi.org/10.3389/fonc.2023.1071030
work_keys_str_mv AT supengxiao targetingcmetinthetreatmentofurologicneoplasmscurrentstatusandchallenges
AT zhangming targetingcmetinthetreatmentofurologicneoplasmscurrentstatusandchallenges
AT kangxin targetingcmetinthetreatmentofurologicneoplasmscurrentstatusandchallenges